500 related articles for article (PubMed ID: 27130449)
1. Chimeric peptide containing both B and T cells epitope of tumor-associated antigen L6 enhances anti-tumor effects in HLA-A2 transgenic mice.
Lin SI; Huang MH; Chang YW; Chen IH; Roffler S; Chen BM; Sher YP; Liu SJ
Cancer Lett; 2016 Jul; 377(2):126-33. PubMed ID: 27130449
[TBL] [Abstract][Full Text] [Related]
2. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
3. Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge.
Daftarian P; Ali S; Sharan R; Lacey SF; La Rosa C; Longmate J; Buck C; Siliciano RF; Diamond DJ
J Immunol; 2003 Oct; 171(8):4028-39. PubMed ID: 14530323
[TBL] [Abstract][Full Text] [Related]
4. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide.
Miconnet I; Koenig S; Speiser D; Krieg A; Guillaume P; Cerottini JC; Romero P
J Immunol; 2002 Feb; 168(3):1212-8. PubMed ID: 11801657
[TBL] [Abstract][Full Text] [Related]
5. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
6. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
7. A HLA-A2-restricted CTL epitope induces anti-tumor effects against human lung cancer in mouse xenograft model.
Sher YP; Lin SI; Chen IH; Liu HY; Lin CY; Chiang IP; Roffler S; Chen HW; Liu SJ
Oncotarget; 2016 Jan; 7(1):671-83. PubMed ID: 26621839
[TBL] [Abstract][Full Text] [Related]
8. Mapping T and B cell epitopes in sperm protein 17 to support the development of an ovarian cancer vaccine.
Xiang SD; Gao Q; Wilson KL; Heyerick A; Plebanski M
Vaccine; 2015 Nov; 33(44):5950-9. PubMed ID: 26263201
[TBL] [Abstract][Full Text] [Related]
9. Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.
Le Gal FA; Prevost-Blondel A; Lengagne R; Bossus M; Farace F; Chaboissier A; Gras-Masse H; Engelhard VH; Guillet JG; Gahéry-Ségard H
Int J Cancer; 2002 Mar; 98(2):221-7. PubMed ID: 11857412
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
Song S; Wang F; He X; He Y; Li D; Sun S
Vaccine; 2007 Jun; 25(25):4853-60. PubMed ID: 17418455
[TBL] [Abstract][Full Text] [Related]
11. Cancer vaccine design: a novel bacterial adjuvant for peptide-specific CTL induction.
Miconnet I; Coste I; Beermann F; Haeuw JF; Cerottini JC; Bonnefoy JY; Romero P; Renno T
J Immunol; 2001 Apr; 166(7):4612-9. PubMed ID: 11254719
[TBL] [Abstract][Full Text] [Related]
12. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication.
Maynard SK; Marshall JD; MacGill RS; Yu L; Cann JA; Cheng LI; McCarthy MP; Cayatte C; Robbins SH
BMC Cancer; 2019 Jun; 19(1):540. PubMed ID: 31170937
[TBL] [Abstract][Full Text] [Related]
14. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
Chaput N; Schartz NE; André F; Taïeb J; Novault S; Bonnaventure P; Aubert N; Bernard J; Lemonnier F; Merad M; Adema G; Adams M; Ferrantini M; Carpentier AF; Escudier B; Tursz T; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2137-46. PubMed ID: 14764679
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
16. H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies.
Firat H; Garcia-Pons F; Tourdot S; Pascolo S; Scardino A; Garcia Z; Michel ML; Jack RW; Jung G; Kosmatopoulos K; Mateo L; Suhrbier A; Lemonnier FA; Langlade-Demoyen P
Eur J Immunol; 1999 Oct; 29(10):3112-21. PubMed ID: 10540322
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
[TBL] [Abstract][Full Text] [Related]
18. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
19. Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen.
Rice J; Buchan S; Stevenson FK
J Immunol; 2002 Oct; 169(7):3908-13. PubMed ID: 12244189
[TBL] [Abstract][Full Text] [Related]
20. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses.
Oseroff C; Sette A; Wentworth P; Celis E; Maewal A; Dahlberg C; Fikes J; Kubo RT; Chesnut RW; Grey HM; Alexander J
Vaccine; 1998 May; 16(8):823-33. PubMed ID: 9627940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
